Enhancing the value of the ASCO value framework

Alec Morton, Peter B. Bach, Andrew Briggs

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
17 Downloads (Pure)


The last few years have seen the development of several “value frameworks” for assessing the relative merits and prices of cancer drugs, including ASCO’s own value framework (Schnipper et al, 2016). These frameworks can have many different aims and audiences (Neumann and Cohen, 2015; Mandelblatt et al, 2017). For example they may be designed to support social decisions about value, as in the case of DrugAbacus . ASCO’s framework is designed to support individual clinical decisions through comparative assessment of treatment alternatives, contemplated as part of the dialogue between patient and physician.

In this paper we inquire as to whether the ASCO framework can be considered as a valid system for measuring patient value, and thus for supporting decisions. We contrast it with some tools which have been developed by those within and affiliated with the Medical Decision Making community, with a view to making constructive suggestions for the ongoing development of the framework.
Original languageEnglish
Number of pages3
JournalMedical Decision Making Policy & Practice
Early online date29 May 2018
Publication statusE-pub ahead of print - 29 May 2018


  • value frameworks
  • cancer drugs
  • ASCO value framework
  • patient value

Cite this